

Supplementary Table 1

Candidate biodefense countermeasures potentially eligible for BARDA funding in FY09

	Company	Product in Pipeline	Phase of Development
Anthrax Vaccines	Avant Immunotherapies, Inc.	Oral anthrax-plague vaccine	Preclinical
	Bio Sante Pharmaceuticals - subcontract with DynPort Vaccine Company LLC	Needle-free anthrax (rPA) vaccine using BioVant™, Bio Sante's calcium phosphate (CaP) nanoparticulate technology	Preclinical
	Fraunhofer USA, Inc.	Plant-derived oral anthrax vaccine	Preclinical
	Ligocyte, Inc.	Dual Antigen Anthrax Vaccine – 3rd generation intranasal, dry powder	Preclinical
	Panacea Biotech, Inc.	Recombinant anthrax vaccine	Preclinical
	Vaxin, Inc.	Adenovirus-vectored nasal anthrax vaccine	Preclinical
	Avant Immunotherapies, Inc.	Injectable vaccine against anthrax	Phase I
	PharmAthene, Inc. (Acquired from Avecia, Ltd. in 2008)	Third-generation rPA - version of Thraxine™ with improved stability	Phase I
	Emergent Biosolutions, Inc.	Next generation anthrax vaccine based on BioThrax® Anthrax Vaccine Adsorbed	Phase I
	PharmAthene, Inc. (Acquired from Avecia, Ltd. In 2008)	Thraxzine™ - recombinant Protective Antigen (rPA), absorbed on Alhydrogel	Phase II
Anthrax Antitoxins	Avanir Pharmaceuticals	AVP-21D9 - human monoclonal antibody for the treatment of anthrax	Preclinical
	Emergent Biosolutions, Inc.	Anthrax Immune Globulin	Preclinical
	IQ Corp.	Anthraxumab™ - Anti-LF human monoclonal antibody	Preclinical

	Elusys Therapeutics, Inc	Anthim™ - high-affinity deimmunized monoclonal antibody, targeting anthrax toxin Protective Antigen	Phase I
	Pharmathene, Inc. and Medarex, Inc.	Valortim™ - fully human antibody designed to target anthrax protective antigen	Phase I
Filovirus Vaccines	Alphavax	Marburg vaccine	Preclinical
	Genphar	Pan-Filovirus vaccine - five subtypes of filovirus	Preclinical
	Crucell	Ebola vaccine	Phase I
	Genphar	Marburg vaccine – trivalent	Phase I
	Genphar	Ebola vaccine – bivalent	Phase I
Filovirus Antivirals	AVI Biopharma	AVI-6002 - ebola antiviral using AVI's NeuGene® technology	Preclinical
	Functional Genetics, Inc.	FGI-103 - host oriented small molecule	Preclinical
	Siga Technologies, Inc.	ST-383 - therapeutic candidate for filoviruses	Preclinical
	Siga Technologies, Inc.	ST-383 - analog therapeutic candidate for filoviruses	Preclinical
Junin virus Antivirals	Siga Technologies, Inc.	ST-193 - therapeutic candidate for New and Old World arenaviruses	Preclinical
	Siga Technologies, Inc.	ST-294 - therapeutic candidate for the New World arenaviruses	Preclinical
Smallpox Antivirals	Biofactura	Monoclonal antibody against smallpox	Preclinical
	Chimerix, Inc.	CMX001	Phase I
	Siga Technologies, Inc.	ST-246	Phase I
	TSRL, Inc.	Cyclic cidofovir prodrug for the treatment and prophylaxis of smallpox	Preclinical
Broad Spectrum Antibiotics[^]	Advanced Life Sciences, Inc.	Cethrymycin - ketolide antibiotic - Gram (+)	Preclinical
	Nanotherapeutics	NanoGENT – Gram(-)	Preclinical

[^] Only broad-spectrum antibiotics with biodefense indications were included.

“Preclinical” refers to confirmed preclinical development candidates deemed to have the potential to enter clinical trials in FY2009.